2020 Medicinal Chemistry Reviews

Volume 55, Chapter 28
To Market, to Market—2019: Macromolecular Therapeutics
Nicholas J. Agard, Peter S. Dragovich, Allison M. Beal, Catherine A. Bolger, Suzana A. Kahn, Brant Hubbard, Daša Lipovšek

1. Brolucizumab (ophthalmology; wet macular degeneration)
2. Camrelizumab (anticancer; Hodgkin’s lymphoma)
3. Crizanlizumab (genetic diseases; sickle cell disease)
4. Enfortumab Vedotin (anticancer; urothelial cancer)
5. Fam-Trastuzumab Deruxtecan (anticancer; breast cancer)
6. Givosiran (genetic diseases; acute hepatic porphyria)
7. Golodirsen (genetic diseases; Duchenne muscular dystrophy)
8. Netakimab (immunology and inflammation; plaque psoriasis)
9. Polatuzumab Vedotin (anticancer; diffuse large B-cell lymphoma)
10. Rabimabs (infectious disease; rabies post-exposure prophylaxis)
11. Risankizumab (immunology and inflammation; plaque psoriasis)
12. Romosozumab (musculoskeletal disease; osteoporosis)
13. Sintilimab (anticancer; Hodgkin’s lymphoma)
14. Tislelizumab (anticancer; Hodgkin’s lymphoma)
15. Toripalimab (anticancer; melanoma)
16. Volanesorsen (genetic diseases; familial chylomicronemia syndrome)

To purchase a copy of this chapter, go to our secure e-commerce site.

ACS Division of Medicinal Chemistry

Webmaster:  secretary@acsmedchem.org